Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 7.6% in November

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 11,230,000 shares, a growth of 7.6% from the October 31st total of 10,440,000 shares. Based on an average trading volume of 733,600 shares, the short-interest ratio is currently 15.3 days. Approximately 20.7% of the shares of the stock are short sold.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. JMP Securities reduced their target price on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating for the company in a research note on Friday, August 9th. Finally, Morgan Stanley initiated coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $86.80.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Teachers Retirement System of The State of Kentucky lifted its stake in shares of Structure Therapeutics by 17.8% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company's stock worth $589,000 after buying an additional 2,077 shares in the last quarter. Mather Group LLC. purchased a new position in Structure Therapeutics in the 2nd quarter worth approximately $214,000. Principal Financial Group Inc. acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $6,489,000. Natixis Advisors LLC grew its position in shares of Structure Therapeutics by 29.4% in the second quarter. Natixis Advisors LLC now owns 19,005 shares of the company's stock valued at $746,000 after purchasing an additional 4,321 shares in the last quarter. Finally, Gilbert & Cook Inc. acquired a new stake in shares of Structure Therapeutics in the second quarter valued at approximately $229,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR traded down $0.69 during trading on Tuesday, reaching $33.25. The stock had a trading volume of 844,629 shares, compared to its average volume of 782,462. Structure Therapeutics has a 1-year low of $26.61 and a 1-year high of $66.38. The stock has a market cap of $1.90 billion, a PE ratio of -44.93 and a beta of -3.41. The business has a fifty day moving average price of $37.83 and a 200-day moving average price of $39.42.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.